🚀 VC round data is live in beta, check it out!
Scandinavian ChemoTech Overview
About Scandinavian ChemoTech
Scandinavian ChemoTech AB is a Sweden based clinical development company. It is engaged in research on pain management and therapy for prostate cancer.
Founded
N/A
HQ
Employees
6
Website
Sectors
Financials (FY)
EV
$10M
Scandinavian ChemoTech Financials
Scandinavian ChemoTech reported last fiscal year revenue of $1M and negative EBITDA of ($450K).
In the same fiscal year, Scandinavian ChemoTech generated $1M in gross profit, ($450K) in EBITDA losses, and had net loss of ($876K).
Revenue (LTM)
Scandinavian ChemoTech P&L
In the most recent fiscal year, Scandinavian ChemoTech reported revenue of $1M and EBITDA of ($450K).
Scandinavian ChemoTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 84% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($450K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (34%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (53%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($876K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (66%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Scandinavian ChemoTech Stock Performance
Scandinavian ChemoTech has current market cap of $10M, and enterprise value of $10M.
Market Cap Evolution
Scandinavian ChemoTech's stock price is $0.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $10M | 0.4% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialScandinavian ChemoTech Valuation Multiples
Scandinavian ChemoTech trades at 7.4x EV/Revenue multiple, and (22.1x) EV/EBITDA.
EV / Revenue (LTM)
Scandinavian ChemoTech Financial Valuation Multiples
As of April 18, 2026, Scandinavian ChemoTech has market cap of $10M and EV of $10M.
Equity research analysts estimate Scandinavian ChemoTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scandinavian ChemoTech has a P/E ratio of (11.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (22.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (14.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.9x | XXX | XXX | XXX |
| P/E | — | XXX | (11.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (21.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Scandinavian ChemoTech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Scandinavian ChemoTech Margins & Growth Rates
Scandinavian ChemoTech's revenue in the last fiscal year grew by 74%.
Scandinavian ChemoTech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Scandinavian ChemoTech's rule of 40 is 76% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scandinavian ChemoTech's rule of X is 187% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Scandinavian ChemoTech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 74% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (34%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (111%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 76% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 187% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 136% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Scandinavian ChemoTech Public Comps
See public comps and valuation multiples for other Medical Devices comps.
Valuation data powered by FactSet, Inc.
Scandinavian ChemoTech M&A Activity
Scandinavian ChemoTech acquired XXX companies to date.
Last acquisition by Scandinavian ChemoTech was on XXXXXXXX, XXXXX. Scandinavian ChemoTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Scandinavian ChemoTech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialScandinavian ChemoTech Investment Activity
Scandinavian ChemoTech invested in XXX companies to date.
Scandinavian ChemoTech made its latest investment on XXXXXXXX, XXXXX. Scandinavian ChemoTech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Scandinavian ChemoTech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Scandinavian ChemoTech
| Where is Scandinavian ChemoTech headquartered? | Scandinavian ChemoTech is headquartered in Sweden. |
| How many employees does Scandinavian ChemoTech have? | As of today, Scandinavian ChemoTech has over 6 employees. |
| Is Scandinavian ChemoTech publicly listed? | Yes, Scandinavian ChemoTech is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Scandinavian ChemoTech? | Scandinavian ChemoTech trades under CMOTEC B ticker. |
| When did Scandinavian ChemoTech go public? | Scandinavian ChemoTech went public in 2016. |
| Who are competitors of Scandinavian ChemoTech? | Scandinavian ChemoTech main competitors are Bluelinea, Sds Optic, Nestmedic, Renalytix. |
| What is the current market cap of Scandinavian ChemoTech? | Scandinavian ChemoTech's current market cap is $10M. |
| What is the current revenue of Scandinavian ChemoTech? | Scandinavian ChemoTech's last fiscal year revenue is $1M. |
| What is the current revenue growth of Scandinavian ChemoTech? | Scandinavian ChemoTech revenue growth (vs. last FY) is 74%. |
| What is the current EV/Revenue multiple of Scandinavian ChemoTech? | Current revenue multiple of Scandinavian ChemoTech is 7.4x. |
| Is Scandinavian ChemoTech profitable? | No, Scandinavian ChemoTech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.